KFAS
INMB icon

Keating Financial Advisory Services’s INmune Bio INMB Stock Holding History

Keating Financial Advisory Services’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226 Hold
200
– – ﹤0.01% 2363
2025
Q4 		$312 Buy
+200
New +$357 ﹤0.01% 2015

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Keating Financial Advisory Services's INMB Position: Q1 2026 in Review

Keating Financial Advisory Services held its INmune Bio (INMB) position steady in Q1 2026 at 200 shares worth $226. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Keating Financial Advisory Services first reported a position in INMB in Q4 2025 and has held it in 2 quarters since. The position peaked at $312 in Q4 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Keating Financial Advisory Services held 200 shares of INmune Bio worth $226 as of Q1 2026.
  • Keating Financial Advisory Services left its INmune Bio share count unchanged in Q1 2026.
  • INmune Bio made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2363 holding.
  • Keating Financial Advisory Services first reported a position in INmune Bio in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's INmune Bio position peaked at $312 in Q4 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.